SR-1375 is under clinical development by Shanghai SIMR Biotech and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia. According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) Pneumonia have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SR-1375’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SR-1375 overview
SR-1375 is under development for the treatment of diabetic macular edema and community acquired pneumonia, hospital acquired pneumonia, coronavirus disease 2019 (covid-19) pneumonia, alzheimers disease and diabetic kidney disease. It is administered through oral route in the form of a capsule.
Shanghai SIMR Biotech overview
Shanghai SIMR Biotech is an innovation-oriented biotech dedicated to the discovery and development of new drugs for pain and other nervous system related diseases. The company is headquartered in Shanghai, China.
For a complete picture of SR-1375’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.